Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

REMEDi4ALL Building a Sustainable European Innovation Platform to Enhance the Repurposing of Medicines for All

Coordinator
Eatris Eric, Netherlands
Runs
1 September 2022 to 31 August 2027
Status
Running
EU funding
€22.6m
Total cost
€22.6m
Partners
28 organisations in 11 countries
Type
Research and Innovation Action
Grant agreement
101057442

What the project is doing

In the project's own words, from its summary on CORDIS.

REMEDi4ALL aims to establish Europe's leadership globally in the repurposing of medicines by creating a vibrant community of practice covering all relevant sectors and disciplines. REMEDi4ALL will establish and operate a permanent European research and innovation platform comprising the complete value chain for cutting edge, patient-focused repurposing, collaborating with users to execute high potential projects at any phase of development, upskilling all stakeholder groups through a comprehensive education and training portfolio, and advancing cross-sectoral policy dialogue with all relevant stakeholders and thought leaders.

The tools and processes developed assembled in REMEDi4ALL will be validated in a portfolio of 4 ambitious preclinical and clinical phase demonstrators, representing high patient need in a variety of disease areas, including oncology, rare and infectious diseases. The REMEDi4ALL platform will operate a complete, harmonised and accessible value chain integrating the scientific, methodological, financial, legal, regulatory, and intellectual property aspects of the repurposing approach in a goal-oriented and patient-centric approach.

Working closely together with research funders and the patient community, REMEDi4ALL will engage and support a substantial user base and concomitant investments through a permanently sustainable entity, working closely with the permanent European Infrastructures and partners. The community of practice comprises leading academic and clinical facilities and infrastructures, medicines regulators, health technology assessors, public agencies and funders, small and large industry, state-of-the-art artificial intelligence and in silico tools, and a global network of collaborators for optimal knowledge exchange.

REMEDi4ALL will substantially increase Europe's capacity to develop high quality repurposed medicines and implement them into the market, through its complete value chain and consensus-based policy development mission.

Topics

Who is involved

OrganisationCityCountryRole
Eatris EricAmsterdamNetherlandsCoordinator
Antikankerfonds - Fonds Anticancer-Anticancer FundMeiseBelgiumParticipant
Medicines for EuropeBruxelles / BrusselBelgiumParticipant
Bundesinstitut Fur Arzneimittel Und MedizinprodukteBonnGermanyParticipant
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen RechtsGoettingenGermanyParticipant
Chemotargets SLBarcelonaSpainParticipant
Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y CajalMadridSpainThird party
Servicio Madrileno De SaludMadridSpainParticipant
Teamit Institute S.l.uBarcelonaSpainThird party
Teamit Research S.l.BarcelonaSpainParticipant
Helsingin YliopistoHelsinkiFinlandParticipant
Ecrin European Clinical Research Infrastructure NetworkParisFranceParticipant
Eurordis - Rare Diseases EuropeParisFranceParticipant
Syreon Kutato Intezet Korlatolt Felelossegu TarsasagBudapestHungaryParticipant
Dompe Farmaceutici SpAMilanoItalyParticipant
Istituto Di Ricerche Farmacologiche Mario NegriMilanoItalyParticipant
ISTITUTO NAZIONALE TUMORI Fondazione PascaleNapoliItalyParticipant
Istituto Ortopedico RizzoliBolognaItalyParticipant
Zorgonderzoek Nederland ZonDen HaagNetherlandsParticipant
Karolinska InstitutetStockholmSwedenParticipant
Uppsala UniversitetUppsalaSwedenParticipant
Univerza V LjubljaniLjubljanaSloveniaParticipant
Beacon: for Rare Diseases LtdCambridgeUnited KingdomAssociatedpartner
LifearcLondonUnited KingdomAssociatedpartner
The University of SheffieldSheffieldUnited KingdomAssociatedpartner
University College LondonLondonUnited KingdomAssociatedpartner
University of HullHullUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI